|
1
|
Slack FJ and Chinnaiyan AM: The role of
non-coding RNAs in oncology. Cell. 179:1033–1055. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Khandelwal A, Bacolla A, Vasquez KM and
Jain A: Long non-coding RNA: A new paradigm for lung cancer. Mol
Carcinog. 54:1235–1251. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Bhat SA, Ahmad SM, Mumtaz PT, Malik AA,
Dar MA, Urwat U, Shah RA and Ganai NA: Long non-coding RNAs:
Mechanism of action and functional utility. Noncoding RNA Res.
1:43–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Thrash-Bingham CA and Tartof KD: aHIF: A
natural antisense transcript overexpressed in human renal cancer
and during hypoxia. J Natl Cancer Inst. 91:143–151. 1999.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rossignol F, Vaché C and Clottes E:
Natural antisense transcripts of hypoxia-inducible factor 1alpha
are detected in different normal and tumour human tissues. Gene.
299:135–140. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen WM, Huang MD, Kong R, Xu TP, Zhang
EB, Xia R, Sun M, De W and Shu YQ: Antisense long noncoding RNA
HIF1A-AS2 is upregulated in gastric cancer and associated with poor
prognosis. Dig Dis Sci. 60:1655–1662. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lin H, Zhao Z, Hao Y and He J and He J:
Long noncoding RNA HIF1A-AS2 facilitates cell survival and
migration by sponging miR-33b-5p to modulate SIRT6 expression in
osteosarcoma. Biochem Cell Biol. 98:284–292. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wu P, Haththotuwa R, Kwok CS, Babu A,
Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham
CA, et al: Preeclampsia and future cardiovascular health: A
systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes.
10(e003497)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Phipps EA, Thadhani R, Benzing T and
Karumanchi SA: Pre-eclampsia: Pathogenesis, novel diagnostics and
therapies (vol 15, pg 275, 2019). Nat Rev Nephrol. 15:386.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Irminger-Finger I, Jastrow N and Irion O:
Preeclampsia: A danger growing in disguise. Int J Biochem Cell
Biol. 40:1979–1983. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ma Y, Liang X, Wu H, Zhang C and Ma Y:
Long non coding RNA NR_002794 is upregulated in pre eclampsia and
regulates the proliferation, apoptosis and invasion of trophoblast
cells. Mol Med Rep. 20:4567–4575. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wu D, Yang N, Xu Y, Wang S, Zhang Y,
Sagnelli M, Hui B, Huang Z and Sun L: lncRNA HIF1A antisense RNA 2
modulates trophoblast cell invasion and proliferation through
upregulating PHLDA1 expression. Mol Ther Nucleic Acids. 16:605–615.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tang X, Liu S, Liu Y, Lin X, Zheng T, Liu
X, Qiu J and Hua K: Circulating serum exosomal aHIF is a novel
prognostic predictor for epithelial ovarian cancer. Onco Targets
Ther. 12:7699–7711. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guler E, Smith DA, Somarouthu B, Gujrathi
R, Ramaiya NH and Tirumani SH: Overview of imaging findings
associated with systemic therapies in advanced epithelial ovarian
cancer. Abdom Radiol (NY). 45:828–841. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Qiu JJ, Lin XJ, Zheng TT, Tang XY and Hua
KQ: Natural antisense transcript of hypoxia-inducible factor 1
regulates hypoxic cell apoptosis in epithelial ovarian cancer. Onco
Targets Ther. 11:9101–9110. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang J, McDowell A, Kim EK, Seo H, Lee WH,
Moon CM, Kym SM, Lee DH, Park YS, Jee YK, et al: Development of a
colorectal cancer diagnostic model and dietary risk assessment
through gut microbiome analysis. Exp Mol Med. 51:1–15.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yuan W, Peng S, Wang J, Wei C, Ye Z, Wang
Y, Wang M, Xu H, Jiang S, Sun D, et al: Identification and
characterization of circRNAs as competing endogenous RNAs for
miRNA-mRNA in colorectal cancer. PeerJ. 7(e7602)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Dong Y, Zhang Y, Kang W, Wang G, Chen H,
Higashimori A, Nakatsu G, Go M, Tong JH, Zheng S, et al: VSTM2A
suppresses colorectal cancer and antagonizes Wnt signaling receptor
LRP6. Theranostics. 9:6517–6531. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lin J, Shi Z, Yu Z and He Z: lncRNA
HIF1A-AS2 positively affects the progression and EMT formation of
colorectal cancer through regulating miR-129-5p and DNMT3A. Biomed
Pharmacother. 98:433–439. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fan H, Jin X, Liao C, Qiao L and Zhao W:
MicroRNA-301b-3p accelerates the growth of gastric cancer cells by
targeting zinc finger and BTB domain containing 4. Pathol Res
Pract. 215(152667)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wan P, Bai X, Yang C, He T, Luo L, Wang Y,
Fan M, Wang Z, Lu L, Yin Y, et al: miR-129-5p inhibits
proliferation, migration, and invasion in rectal adenocarcinoma
cells through targeting E2F7. J Cell Physiol. 235:5689–5701.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang LL, Zhang L and Cui XF:
Downregulation of long noncoding RNA LINC01419 inhibits cell
migration, invasion, and tumor growth and promotes autophagy via
inactivation of the PI3K/Akt1/mTOR pathway in gastric cancer. Ther
Adv Med Oncol. 11(1758835919874651)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lee KL, Kuo YC, Ho YS and Huang YH:
Triple-negative breast cancer: Current understanding and future
therapeutic breakthrough targeting cancer Stemness. Cancers
(Basel). 11(1334)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Khan MA, Jain VK, Rizwanullah M, Ahmad J
and Jain K: PI3K/AKT/mTOR pathway inhibitors in triple-negative
breast cancer: A review on drug discovery and future challenges.
Drug Discov Today. 24:2181–2191. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Song N, Zhao L, Zhu M and Zhao J:
99mTc-Labeled LyP-1 for SPECT Imaging of Triple Negative Breast
Cancer. Contrast Media Mol Imaging. 2019(9502712)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Guo X, Lee S and Cao P: The inhibitive
effect of sh-HIF1A-AS2 on the proliferation, invasion, and
pathological damage of breast cancer via targeting miR-548c-3p
through regulating HIF-1α/VEGF pathway in vitro and vivo. Onco
Targets Ther. 12:825–834. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu
KD and Shao ZM: Transcriptome Analysis of triple-negative breast
cancer reveals an integrated mRNA-lncRNA signature with predictive
and prognostic value. Cancer Res. 76:2105–2114. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yu G, Zhou H, Yao W, Meng L and Lang B:
lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via
epigenetically silencing miR-194-5p in bladder cancer. Mol Ther
Nucleic Acids. 16:257–271. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Miao L, Liu HY, Zhou C and He X: LINC00612
enhances the proliferation and invasion ability of bladder cancer
cells as ceRNA by sponging miR-590 to elevate expression of PHF14.
J Exp Clin Cancer Res. 38(143)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhuang C, Ma Q, Zhuang C, Ye J, Zhang F
and Gui Y: lncRNA GClnc1 promotes proliferation and invasion of
bladder cancer through activation of MYC. FASEB J. 33:11045–11059.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia
M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA
targeting antisense long non-coding RNA HIF1A-AS2 represses the
malignant phenotypes of bladder cancer. Cancer Lett. 376:155–164.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Qi X, Yu XJ, Wang XM, Song TN, Zhang J,
Guo XZ, Li GJ and Shao M: Knockdown of KCNQ1OT1 suppresses cell
invasion and sensitizes osteosarcoma cells to CDDP by upregulating
DNMT1-mediated Kcnq1 expression. Mol Ther Nucleic Acids.
17:804–818. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jiang N, Wang X, Xie X, Liao Y, Liu N, Liu
J, Miao N, Shen J and Peng T: lncRNA DANCR promotes tumor
progression and cancer stemness features in osteosarcoma by
upregulating AXL via miR-33a-5p inhibition. Cancer Lett. 405:46–55.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang CL, Zhu KP and Ma XL: Antisense
lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by
increasing the expression of FOXC2. Cancer Lett. 396:66–75.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhong L, Liao D, Li JJ, Liu WQ, Wang JX,
Zeng CL, Wang X, Cao ZL, Zhang RH, Li M, et al: Rab22a-NeoF1 fusion
protein promotes osteosarcoma lung metastasis through its secretion
into exosomes. Signal Transduct Target Ther. 6(59)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang X, Peng L, Gong X, Zhang X and Sun R:
lncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a
sponge of miR-129-5p. Aging (Albany NY). 11:11803–11813.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tang C, Wang Y, Zhang L, Wang J, Wang W,
Han X, Mu C and Gao D: Identification of novel lncRNA targeting
Smad2/PKCα signal pathway to negatively regulate malignant
progression of glioblastoma. J Cell Physiol. 235:3835–3848.
2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ji J, Xu R, Ding K, Bao G, Zhang X, Huang
B, Wang X, Martinez A, Wang X, Li G, et al: Long Noncoding RNA
SChLAP1 forms a growth-promoting complex with HNRNPL in human
glioblastoma through stabilization of ACTN4 and activation of NF-κB
signaling. Clin Cancer Res. 25:6868–6881. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mineo M, Ricklefs F, Rooj AK, Lyons SM,
Ivanov P, Ansari KI, Nakano I, Chiocca EA, Godlewski J and Bronisz
A: The Long Non-coding RNA HIF1A-AS2 facilitates the maintenance of
mesenchymal glioblastoma stem-like cells in hypoxic niches. Cell
Rep. 15:2500–2509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang L, Babikir H, Müller S, Yagnik G,
Shamardani K, Catalan F, Kohanbash G, Alvarado B, Di Lullo E,
Kriegstein A, et al: The phenotypes of proliferating glioblastoma
cells reside on a single axis of variation. Cancer Discov.
9:1708–1719. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bhat KPL, Balasubramaniyan V, Vaillant B,
Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L,
James JD, Goodman LD, et al: Mesenchymal differentiation mediated
by NF-κB promotes radiation resistance in glioblastoma. Cancer
Cell. 24:331–346. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liao K, Ma X, Chen B, Lu X, Hu Y, Lin Y,
Huang R and Qiu Y: Upregulated AHIF-mediated radioresistance in
glioblastoma. Biochem Biophys Res Commun. 509:617–623.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kovacs G, Wilkens L, Papp T and de Riese
W: Differentiation between papillary and nonpapillary renal cell
carcinomas by DNA analysis. J Natl Cancer Inst. 81:527–530.
1989.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Korenaga Y, Naito K, Okayama N, Hirata H,
Suehiro Y, Hamanaka Y, Matsuyama H and Hinoda Y: Association of the
BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int
J Cancer. 117:431–434. 2005.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhang C, Huang D, Liu A, Xu Y, Na R and Xu
D: Genome-wide screening and cohorts validation identifying novel
lncRNAs as prognostic biomarkers for clear cell renal cell
carcinoma. J Cell Biochem. 121:2559–2570. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhu Y, Yang Z, Chen H, Pan Y, Gong L, Chen
F, Jin X, Wen S, Li Y and Chen G: lncRNAHIF1A-AS2 promotes renal
carcinoma cell proliferation and migration via miR-130a-5p/ERBB2
pathway. Onco Targets Ther. 13:9807–9820. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
The Lancet: Lung cancer: Some progress,
but still a lot more to do. The Lancet. 394(1880)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Dawson Q: NELSON trial: Reduced
lung-cancer mortality with volume CT screening. Lancet Respir Med.
8:236. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zhang W, Liu K, Pei Y, Tan J, Ma J and
Zhao J: Long noncoding RNA HIF1A-AS2 promotes non-small cell lung
cancer progression by the miR-153-5p/S100A14 axis. Onco Targets
Ther. 13:8715–8722. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wang P: The Opening of Pandora's Box: An
emerging role of long noncoding RNA in viral infections. Front
Immunol. 9(3138)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Mu L, Wang Y, Su H, Lin Y, Sui W, Yu X and
Lv Z: HIF1A-AS2 promotes the proliferation and metastasis of
gastric cancer cells through miR-429/PD-L1 axis. Dig Dis Sci Feb 8,
2021 (Epub ahead of print). doi: 10.1007/s10620-020-06819-w.
|
